Dignitana Partners with ThermoTek to Develop Next Generation in Scalp Cooling

DigniCap Delta brings advanced cooling technology to minimize hair loss from chemotherapy 

Files for download
Dignitana Release - wkr0006.pdf

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, has partnered with ThermoTek, Inc. to develop the DigniCap Delta, an advanced model of the 2015 FDA-cleared DigniCap Scalp Cooling System, featuring a new single-patient use cap design and a smaller, more streamlined single-patient machine. U.S. Food and Drug Adminstration clearance for the new device is anticipated in spring 2019.

As contract development and manufacturing partner in the creation of the DigniCap Delta, ThermoTek brings more than twenty-five years of experience as a leader in the medical device industry and has spearheaded award-winning designs for precision thermal management solutions and compression therapies.

“Precise temperature control is critical to scalp cooling success and ensuring maximum comfort for patients,” said William Cronin, Chief Executive Officer of Dignitana AB. “With more than 89 technological patents in its medical device portfolio, ThermoTek’s proven track record allows us to confidently offer both patients and clinicians the safest, most advanced solution to chemotherapy related hair loss in a new, simple-to-use, custom-control system. As ThermoTek is also based here in Dallas, we are able to rapidly incorporate new ideas and feedback from partner sites and patients into our product development process.”

In addition to enhanced cooling technology, the DigniCap Delta introduces new features that include device portability, a more intuitive user interface, quieter operation, and an advanced ergonomic design with faster connections to improve patient comfort and clinical staff access.

“We are proud to partner with Dignitana and bring a new generation of technology to the world of scalp cooling therapeutics’,” said Sam McSpadden, Chief Executive Officer of ThermoTek. “This partnership has given us an opportunity to apply our proven technology in a meaningful, critical and impactful way, helping cancer patients worldwide improve their quality of life. We look forward to working with Dignitana for many years to come, continuing to improve the process of scalp cooling to provide the best possible patient outcomes.”

Until the creation of scalp cooling, hair loss was deemed an inevitable side effect of chemotherapy and it continues to serve as an often-unwelcome reminder of the disease to cancer patients. An estimated 10 percent of female patients decline prescribed chemotherapy out of fear of losing their hair, making greater accessibility to scalp cooling a vital component of cancer care.

This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 0845 on 19 December 2018.

For more information contact:

William Cronin, CEO, Dignitana AB bill.cronin@dignitana.com    +1 469-917-5555

Mikael Wahlgren, Deputy Managing Director, Dignitana AB mikael.wahlgren@dignitana.com   +46 709 33 72 20

About Dignitana AB (publ) 

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. Dignitana AB is listed on Nasdaq First North Stockholm in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank is Certified Adviser. Learn more at www.dignitana.se and www.dignicap.com.

About ThermoTek

ThermoTek has been a leader in the medical device industry for twenty-five years.  With innovative designs for precision thermal management solutions, compression therapies and numerous patents on technology, ThermoTek continues to push the envelope with new and creative product offerings. Visit  www.thermotekusa.com. 

Company Contact

William Cronin, Chief Executive Officer, Dignitana AB  bill.cronin@dignitana.com +1 469 917 5555

Mikael Wahlgren, Deputy Managing Director, Dignitana AB  mikael.wahlgren@dignitana.com   +46 709 33 72 20